Please assess the completion status of the following clinical trial:

Trial Title: CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria~* Baseline Crohn's Disease Activity Index (CDAI) 250-400, inclusive~* Crohn's disease of at least 3 months duration, with colitis, ileitis, or ileocolitis, confirmed by radiography and/or endoscopy~* Patients receiving medications for CD must be on stable doses entering the study~* Any CD medication which has been discontinued must have been discontinued at least 4 weeks prior to screening, with the exception of infliximab, which must have been discontinued at least 8 weeks prior to screening~Exclusion Criteria~* Patients with any ostomy or extensive bowel resection~* Current evidence of bowel obstruction or history within the preceding six months as confirmed by radiography, endoscopy, or surgery~* Patients with stool examination positive for enteric pathogens, pathogenic ova or parasites, or Clostridium difficile toxin~* Treatment with any other experimental therapeutics within the last 4 weeks before enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Semapimod 60 mg (Type: EXPERIMENTAL): Semapimod 60 mg IV x 5 days
- Semapimod IV 30 mg (Type: EXPERIMENTAL): Semapimod IV 30 mg x 5 days
- Placebo (Type: PLACEBO_COMPARATOR): Placebo IV x 3 or 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).